Was the Pfizer-Allergan merger proposal really a windfall for Ireland?

When new rules proposed by the US Treasury stopped the $160 billion Pfizer-Allergan super-inversion in early April many Americans applauded. Some grumbled about unfair tax loopholes or blamed Ireland’s 12.5% corporate tax for luring away American companies who pay up to 35% tax back home.

Locked content

The article you are trying to view is only available to subscribers and current trialists